PRCT on Nasdaq
PROCEPT BioRobotics Corp
In its 2026 annual report the company says: “We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH.”4 It is headquartered in San Jose, California.1 Its shares trade on Nasdaq under the symbol PRCT.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with SkinHealth Systems Inc., ANGIODYNAMICS INC or TACTILE SYSTEMS TECHNOLOGY INC, or pick any stock.
- TickerPRCT on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersSan Jose, California1
- Incorporated inDE2
- Business address150 Baytech Drive, San Jose, Ca 951342
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes. We believe t…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
63.7%Gross margin5
-33.7%Operating margin5
-31.0%Net margin5
37.2%Revenue growth, 20255
-26.1%Return on equity5
0.14×Debt to equity5
-$58.3MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 88% of the revenue PROCEPT BioRobotics Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $124.3M | $200.5M | $270.4M |
| Outside the United States | $11.9M | $24.0M | $37.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$111.8M
- Research and development17¢$71.3M
- Selling, general and admin56¢$228.8M
- Income tax0¢$190.0K
Out of $308.1M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M |
| Cost of sales | $111.8M | $87.4M | $65.1M |
| Gross profit | $196.2M | $137.1M | $71.0M |
| Research and development | $71.3M | $62.3M | $48.4M |
| Selling, general and administrative | $228.8M | $171.4M | $131.8M |
| Total operating expenses | $300.1M | $233.7M | $180.2M |
| Loss from operations | -$103.9M | -$96.6M | -$109.2M |
| Interest expense | -$3.6M | -$4.2M | -$4.0M |
| Interest and other income (expenses), net | $12.1M | $9.8M | $7.3M |
| Loss before income taxes | -$95.4M | -$91.0M | -$105.8M |
| Provision for income taxes | $190.0K | $368.0K | $80.0K |
| Net loss | -$95.6M | -$91.4M | -$105.9M |
| Net loss per share, basic (in dollars per share) | -$1.72 | -$1.75 | -$2.24 |
| Net loss per share, diluted (in dollars per share) | -$1.72 | -$1.75 | -$2.24 |
| Basic (in shares) | 55.5M shares | 52.1M shares | 47.3M shares |
| Diluted (in shares) | 55.5M shares | 52.1M shares | 47.3M shares |
| Foreign currency translation adjustment | -$77.0K | $0 | $0 |
| Unrealized gain on cash equivalents | $0 | $30.0K | $90.0K |
| Comprehensive loss | -$95.6M | -$91.4M | -$105.8M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $286.5M | $333.7M | $257.2M | |
| Accounts receivable, net, | $83.5M | $83.5M | ||
| Inventory | $70.7M | $56.2M | ||
| Prepaid expenses and other current assets | $9.6M | $8.5M | ||
| Total current assets | $450.4M | $481.8M | ||
| Restricted cash, non-current | $3.0M | $3.0M | ||
| Property and equipment, net | $30.4M | $26.7M | ||
| Operating lease right-of-use assets, net | $17.5M | $18.9M | ||
| Intangible assets, net | $709.0K | $932.0K | ||
| Other assets | $6.0M | $2.6M | ||
| Total assets | $508.1M | $534.0M | ||
| Accounts payable | $17.3M | $10.0M | ||
| Accrued compensation | $23.2M | $21.5M | ||
| Deferred revenue | $13.0M | $9.6M | ||
| Operating leases, current | $2.2M | $1.9M | ||
| Loan facility derivative liability | $0 | $2.0M | ||
| Other current liabilities | $10.1M | $8.1M | ||
| Total current liabilities | $65.8M | $53.1M | ||
| Long-term debt | $51.6M | $51.5M | ||
| Operating leases, non-current | $24.7M | $26.9M | ||
| Other non-current liabilities | $147.0K | $324.0K | ||
| Total liabilities | $142.2M | $131.8M | ||
| Preferred stock, $0.00001 par value; authorized shares: 10,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: none at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.00001 par value; authorized shares: 300,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: 54,718 and 50,771 at December 31, 2025 and 2024 | $0 | $0 | ||
| Additional paid-in capital | $1.0B | $948.1M | ||
| Accumulated other comprehensive gain | $37.0K | $114.0K | ||
| Accumulated deficit | -$641.6M | -$546.0M | ||
| Total stockholders equity | $365.9M | $402.2M | $280.8M | $197.1M |
| Total liabilities and stockholders equity | $508.1M | $534.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred Stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued (in shares) | 56.3M shares | 54.7M shares | ||
| Common stock, shares, outstanding (in shares) | 56.3M shares | 54.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $286.5M | $333.7M | $257.2M | |
| Accounts receivable, net, | $83.5M | $83.5M | ||
| Inventory | $70.7M | $56.2M | ||
| Prepaid expenses and other current assets | $9.6M | $8.5M | ||
| Total current assets | $450.4M | $481.8M | ||
| Restricted cash, non-current | $3.0M | $3.0M | ||
| Property and equipment, net | $30.4M | $26.7M | ||
| Operating lease right-of-use assets, net | $17.5M | $18.9M | ||
| Intangible assets, net | $709.0K | $932.0K | ||
| Other assets | $6.0M | $2.6M | ||
| Total assets | $508.1M | $534.0M | ||
| Accounts payable | $17.3M | $10.0M | ||
| Accrued compensation | $23.2M | $21.5M | ||
| Deferred revenue | $13.0M | $9.6M | ||
| Operating leases, current | $2.2M | $1.9M | ||
| Loan facility derivative liability | $0 | $2.0M | ||
| Other current liabilities | $10.1M | $8.1M | ||
| Total current liabilities | $65.8M | $53.1M | ||
| Long-term debt | $51.6M | $51.5M | ||
| Operating leases, non-current | $24.7M | $26.9M | ||
| Other non-current liabilities | $147.0K | $324.0K | ||
| Total liabilities | $142.2M | $131.8M | ||
| Preferred stock, $0.00001 par value; authorized shares: 10,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: none at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.00001 par value; authorized shares: 300,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: 54,718 and 50,771 at December 31, 2025 and 2024 | $0 | $0 | ||
| Additional paid-in capital | $1.0B | $948.1M | ||
| Accumulated other comprehensive gain | $37.0K | $114.0K | ||
| Accumulated deficit | -$641.6M | -$546.0M | ||
| Total stockholders equity | $365.9M | $402.2M | $280.8M | $197.1M |
| Total liabilities and stockholders equity | $508.1M | $534.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred Stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued (in shares) | 56.3M shares | 54.7M shares | ||
| Common stock, shares, outstanding (in shares) | 56.3M shares | 54.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$95.6M | -$91.4M | -$105.9M |
| Depreciation and amortization | $6.4M | $5.2M | $3.8M |
| Stock-based compensation expense | $47.6M | $31.8M | $19.1M |
| Change in fair value in derivative liability | $0 | $114.0K | $107.0K |
| Non-cash lease adjustment | -$508.0K | -$383.0K | $13.0K |
| Provision for credit losses | $219.0K | $840.0K | $0 |
| Inventory write-down | $565.0K | $1.9M | $995.0K |
| (Gain) loss on foreign currency transactions | $157.0K | $0 | $0 |
| Accounts receivable, net | -$898.0K | -$36.0M | -$33.1M |
| Inventory | -$14.5M | -$17.2M | -$9.8M |
| Prepaid expenses and other current assets | -$1.1M | -$3.2M | $1.1M |
| Other assets | -$2.9M | -$1.6M | -$868.0K |
| Accounts payable | $6.6M | -$2.2M | $5.8M |
| Accrued compensation | $1.6M | $4.7M | $3.4M |
| Accrued interest expense | $142.0K | $134.0K | $125.0K |
| Loan facility liability | -$2.0M | $0 | $0 |
| Deferred revenue | $3.3M | $3.7M | $3.3M |
| Reimbursements for leasehold improvements from operating leases | $0 | $2.6M | $5.0M |
| Other liabilities | $1.9M | $1.8M | -$1.1M |
| Net cash used in operating activities | -$49.0M | -$99.2M | -$108.0M |
| Purchases of property and equipment | -$9.4M | -$4.4M | -$25.2M |
| Net cash used in investing activities | -$9.4M | -$4.4M | -$25.2M |
| Proceeds from issuance of common stock under employee stock purchase plan | $6.4M | $4.5M | $3.6M |
| Proceeds from issuance of common stock from the exercise of stock options, net | $4.8M | $11.1M | $2.5M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $164.5M | $161.7M |
| Net cash provided by financing activities | $11.2M | $180.1M | $167.8M |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -$74.0K | $0 | $0 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$47.2M | $76.5M | $34.6M |
| Interest paid | $3.5M | $4.0M | $4.1M |
| Property and equipment included in accounts payable and accrued expenses | $969.0K | $348.0K | $1.9M |
No quarter-by-quarter statement was filed.
Corporate structure
PROCEPT BioRobotics Corp sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of PROCEPT BioRobotics Corp
- BlackRock Filed SCHEDULE 13G/A on PROCEPT BioRobotics Corp, latest Jul 29, 2026 (2 filings since Jan 26, 2024)
- AllianceBernstein Filed SCHEDULE 13G/A on PROCEPT BioRobotics Corp, latest May 18, 2026 (2 filings since Nov 14, 2025)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on PROCEPT BioRobotics Corp, latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on PROCEPT BioRobotics Corp, latest Mar 27, 2026 (5 filings since Feb 9, 2023)
- FMR LLC Filed SCHEDULE 13G/A on PROCEPT BioRobotics Corp, latest Mar 6, 2026 (6 filings since Feb 9, 2022)
- T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G on PROCEPT BioRobotics Corp, latest Feb 17, 2026 (4 filings since Feb 14, 2023)
- BNP Paribas Asset Management Holding S.A. Filed SCHEDULE 13G on PROCEPT BioRobotics Corp, latest Feb 11, 2026
- CPMG Inc Filed SC 13D/A on PROCEPT BioRobotics Corp, latest May 22, 2024 (6 filings since Sep 8, 2022)
- VIKING GLOBAL INVESTORS LP Filed SC 13G/A on PROCEPT BioRobotics Corp, latest Feb 14, 2023 (3 filings since Feb 14, 2022)
- PROCEPT BioRobotics Corp San Jose, California
- PROCEPT BioRobotics K.K. Subsidiary · Japan
- PROCEPT BioRobotics UK Ltd. Subsidiary · United Kingdom
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What PROCEPT BioRobotics Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $43.2M5 Dec 31, 2025 | $34.5M5 Dec 31, 2024 | +24.9% |
| Accumulated depreciation | $12.8M5 Dec 31, 2025 | $7.8M5 Dec 31, 2024 | +62.9% |
| Property and equipment, net | $30.4M5 Dec 31, 2025 | $26.7M5 Dec 31, 2024 | +13.8% |
| Operating-lease assets (leased space) | $17.5M5 Dec 31, 2025 | $18.9M5 Dec 31, 2024 | −7.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $286.5M5 Dec 31, 2025 | $333.7M5 Dec 31, 2024 | −14.1% |
Intangibles and goodwill
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $70.7M5 Dec 31, 2025 | $56.2M5 Dec 31, 2024 | +25.9% |
| Raw materials | $18.6M5 Dec 31, 2025 | $18.2M5 Dec 31, 2024 | +2.4% |
| Work in process | $13.4M5 Dec 31, 2025 | $11.5M5 Dec 31, 2024 | +17.4% |
| Finished goods | $38.6M5 Dec 31, 2025 | $26.5M5 Dec 31, 2024 | +45.6% |
Properties, in its own words
Our principal office is located at 150 Baytech Drive, San Jose, California, where we lease approximately 158,221 square feet of office space. The principal office lease commenced in July 2022, and will continue for 122 months thereafter, with two five-year options to extend the term of the lease.
Item 2 of the 10-K filed Feb 26, 2026.4
Leadership
Who has led PROCEPT BioRobotics Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerLarry L. Wood Sep 4, 2025 to now12
- Chief executive officerReza Zadno Sep 14, 2021 to Sep 4, 202513
- PresidentLarry L. Wood Sep 4, 2025 to now12
- PresidentReza Zadno Sep 14, 2021 to Sep 4, 202513
- Chief financial officerKevin Waters Sep 14, 2021 to now14
Board members and other officers (16)
- Chief Strat/Marketing OfficerPooja Sharma Apr 24, 2026 to now15
- EVP, Chief Technology OfficerBarry L. Templin Apr 30, 2026 to now16
- SVP, GEN COUNSEL, CORP. SEC.Alaleh Nouri Sep 14, 2021 to Sep 14, 202117
- SVP, Commercial OperationsHisham Shiblaq Sep 14, 2021 to now18
- Board memberLarry L. Wood Apr 19, 2024 to now19
- Board memberThomas M. Prescott Jul 19, 2024 to now20
- Board memberMary Garrett Jan 3, 2022 to now21
- Board memberAmy M. Dodrill Sep 14, 2021 to now22
- Board memberAntal Rohit Desai Sep 14, 2021 to now23
- Board memberFrederic H. Moll Sep 14, 2021 to now24
- Board memberMorgan Colby Wood Sep 14, 2021 to Nov 14, 202325
- Board memberReza Zadno Sep 14, 2021 to now13
- Board memberTaylor C. Harris Sep 14, 2021 to now26
- Board memberThomas M. Krummel Sep 14, 2021 to Jun 6, 202427
- Board memberElisabeth Sandoval Oct 25, 2021 to now28
- General counselAlaleh Nouri Apr 4, 2022 to now29
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- PROCEPT BioRobotics GmbH Germany3
- PROCEPT BioRobotics K.K. Japan3
- PROCEPT BioRobotics UK Ltd. United Kingdom3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Oct 2, 20268-K Executive or director change30
- Sep 24, 20268-K Entered a material agreement31
- Aug 4, 20268-K Results of operations32
- Jun 10, 20268-K Shareholder vote33
- Apr 29, 20268-K Results of operations34
- Mar 6, 20268-K Executive or director change35
- Feb 26, 20268-K Regulation FD disclosure36
- Feb 25, 20268-K Results of operations37
- Nov 4, 20258-K Results of operations38
- Sep 18, 20258-K Executive or director change39
- Sep 4, 2025New chief executive Larry L. Wood becomes CEO12
- Aug 6, 20258-K Results of operations40
- Jul 25, 20258-K Results of operations; Executive or director change; Regulation FD disclosure41
- Sep 14, 2021New chief executive Reza Zadno becomes CEO13
Calendar
Coming up
- Nov 4, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported ($0.38) a share, on Nov 4, 2025.42
When it reported results
- Aug 4, 2026Reported quarterly or annual results32
- Apr 29, 2026Reported quarterly or annual results34
- Feb 25, 2026Reported quarterly or annual results37
- Nov 4, 2025Reported quarterly or annual results38
- Aug 6, 2025Reported quarterly or annual results40
- Jul 25, 2025Reported quarterly or annual results41
- Apr 24, 2025Reported quarterly or annual results43
- Feb 25, 2025Reported quarterly or annual results44
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
339 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 47 major events, 173 insider forms, 30 large holders, 67 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 5, 20263 EDGAR
- Oct 2, 20268-K EDGAR
- Sep 24, 20268-K EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 2026144 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 10, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G/A EDGAR
- Jun 10, 20264 EDGAR
- Jun 10, 20264 EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
97 open-market trades by officers, directors and large owners since October 2021: 6 buys and 91 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Waters KevinEVP, CFO | Sale | 373 | $20.95 | $7.8K | Form 4 |
| Sep 9, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 297 | $20.95 | $6.2K | Form 4 |
| Sep 9, 2026 | Templin Barry LEVP, Chief Technology Officer | Sale | 373 | $20.95 | $7.8K | Form 4 |
| Aug 7, 2026 | Wood Larry LPresident, CEO | Buy | 23,900 | $20.85 | $498.3K | Form 4 |
| Jun 8, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 285 | $28.48 | $8.1K | Form 4 |
| Jun 8, 2026 | Waters KevinEVP, CFO | Sale | 357 | $28.48 | $10.2K | Form 4 |
| Jun 8, 2026 | Templin Barry LEVP, Chief Technology Officer | Sale | 358 | $28.48 | $10.2K | Form 4 |
| Mar 19, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 5,363 | $25.96 | $139.2K | Form 4 |
| Mar 17, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 304 | $28.15 | $8.6K | Form 4 |
| Mar 17, 2026 | Waters KevinEVP, CFO | Sale | 706 | $28.15 | $19.9K | Form 4 |
| Mar 10, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 3,243 | $25.65 | $83.2K | Form 4 |
| Mar 9, 2026 | Desai Antal RohitDirector | Buy | 98,699 | $24.55 | $2.4M | Form 4 |
| Mar 6, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 6,892 | $23.70 | $163.3K | Form 4 |
| Mar 6, 2026 | Waters KevinEVP, CFO | Sale | 6,721 | $23.70 | $159.3K | Form 4 |
| Mar 6, 2026 | Desai Antal RohitDirector | Buy | 160,317 | $23.59 | $3.8M | Form 4 |
| Mar 5, 2026 | Desai Antal RohitDirector | Buy | 167,246 | $25.58 | $4.3M | Form 4 |
| Aug 13, 2025 | MOLL FREDERIC HDirector | Buy | 20,000 | $39.26 | $785.2K | Form 4 |
| Jun 12, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $61.49 | $1.5M | Form 4 |
| Jun 11, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $63.38 | $1.6M | Form 4 |
| Jun 10, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $63.91 | $1.6M | Form 4 |
All 97 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 2 filings Jan 26, 2024 to Jul 29, 202645
- AllianceBernsteinSCHEDULE 13G/A, 2 filings Nov 14, 2025 to May 18, 202646
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202647
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 9, 2023 to Mar 27, 202648
- FMR LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Mar 6, 202649
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G, 4 filings Feb 14, 2023 to Feb 17, 202650
- BNP Paribas Asset Management Holding S.A.SCHEDULE 13G, 1 filing Feb 11, 202651
- CPMG IncSC 13D/A, 6 filings Sep 8, 2022 to May 22, 202452
- VIKING GLOBAL INVESTORS LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202353
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Larry L. WoodPresident & Chief Executive Officer | 60 | $304.8K | $16.8M54 |
| 2025 | Reza Zadno, Ph.D.Former President & Chief Executive Officer | $471.3K | $6.8M54 | |
| 2025 | Kevin WatersEVP, Chief Financial Officer | 48 | $502.2K | $2.8M54 |
| 2025 | Alaleh NouriEVP, Chief Legal Officer & Corporate Secretary | 47 | $471.5K | $2.3M54 |
| 2025 | Hisham ShiblaqFormer EVP, Chief Commercial Officer | $336.0K | $2.0M54 | |
| 2024 | Reza Zadno, Ph.D.Former President & Chief Executive Officer | $671.9K | $6.5M54 | |
| 2024 | Hisham ShiblaqFormer EVP, Chief Commercial Officer | $477.5K | $3.6M54 | |
| 2024 | Alaleh NouriEVP, Chief Legal Officer & Corporate Secretary | 47 | $448.8K | $2.7M54 |
| 2024 | Kevin WatersEVP, Chief Financial Officer | 48 | $482.5K | $2.2M54 |
| 2023 | Reza Zadno, Ph.D.Former President & Chief Executive Officer | $612.6K | $6.1M54 | |
| 2023 | Kevin WatersEVP, Chief Financial Officer | 48 | $448.8K | $2.7M54 |
| 2023 | Hisham ShiblaqFormer EVP, Chief Commercial Officer | $430.0K | $2.6M54 | |
| 2023 | Alaleh NouriEVP, Chief Legal Officer & Corporate Secretary | 47 | $410.8K | $2.2M54 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,869,828 | $110.0M | 0.0% | +507,826 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,823,849 | $63.8M | 0.1% | −265,529 |
| Vanguard Portfolio Management LLC | 2,526,802 | $57.1M | 0.0% | +105,440 |
| Vanguard Capital Management LLC | 2,460,802 | $55.6M | 0.0% | +61,735 |
| Chicago Capital, LLC | 2,073,237 | $46.8M | 1.1% | −87,350 |
| State Street Corp | 1,617,475 | $36.5M | 0.0% | +87,844 |
| Geode Capital Management, LLC | 1,484,163 | $33.5M | 0.0% | +120,663 |
| Fmr LLC | 1,444,878 | $32.6M | 0.0% | −17,026 |
| Wellington Management Group Llp | 1,274,004 | $28.8M | 0.0% | +412,399 |
| Federated Hermes, Inc. | 1,253,420 | $28.3M | 0.0% | +1,078,984 |
| Jupiter Topco LLC | 1,103,404 | $24.9M | 0.0% | New |
| Frontier Capital Management Co LLC | 1,091,528 | $24.6M | 0.2% | +481,671 |
| Soleus Capital Management, L.P. | 1,003,000 | $22.6M | 0.8% | +843,000 |
| Champlain Investment Partners, LLC | 981,381 | $22.2M | 0.6% | −154,941 |
| Baillie Gifford & Co | 911,751 | $20.6M | 0.0% | −61,751 |
| Fiera Capital Corp | 774,569 | $17.5M | 0.1% | −193,026 |
| LMR Partners LLP | 721,608 | $16.3M | 0.1% | New |
| William Blair Investment Management, LLC | 709,484 | $16.0M | 0.0% | +285,175 |
| Artisan Partners Limited Partnership | 682,588 | $15.4M | 0.0% | −504,761 |
| Millennium Management LLC | 624,312 | $14.1M | 0.0% | −381,146 |
| Morgan Stanley | 605,407 | $13.7M | 0.0% | −372,000 |
| Northern Trust Corp | 597,549 | $13.5M | 0.0% | +45,531 |
| Blair William & Co/il | 531,724 | $12.0M | 0.0% | +207,789 |
| New York State Common Retirement Fund | 524,358 | $11.8M | 0.0% | +84,302 |
| Bank Of America Corp /de/ | 516,198 | $11.7M | 0.0% | −114,491 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How PROCEPT BioRobotics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPROCEPT BioRobotics Corp1
- CIK0001588978
- Employer ID (EIN)26-01991804
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address150 Baytech Drive, San Jose, CA 951341
- Phone65023298321
- Shares outstanding57,273,659 as of Jul 31, 202610
- Public float$3.2B as of Jun 30, 20254
- AuditorPricewaterhouseCoopers LLP, San Jose, California PCAOB ID 238; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceOct 15, 20131
- Filings394 in all: 4 (178), 8-K (48), 144 (44), 3 (16), 10-Q (15), SC 13G/A (10), D (7), S-8 (6)1
All 36 form types
SC 13D/A (6), SC 13G (6), 10-K (5), CORRESP (5), DEF 14A (5), DEFA14A (5), SCHEDULE 13G/A (5), 424B5 (4), SCHEDULE 13G (4), 4/A (3), SD (3), UPLOAD (3), 10-K/A (1), 10-Q/A (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3ASR (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Oct 2, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, $0.00001 par value per share | PRCT | Nasdaq Global Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks PROCEPT BioRobotics Corp names in Item 1A of its 10-K filed Feb 26, 2026: 74 risks under these headings, as written.4
- Risks Related to Our Business
- We have a history of significant net losses, we expect to continue to incur operating losses for the foreseeable future and we may not be able to achieve or sustain profitability.
- Our revenue is primarily generated from sales of our robotic systems and the accompanying single-use disposable handpieces, and we are therefore highly dependent on the success of those products.
- Our quarterly and annual operating results may fluctuate significantly and may not fully reflect the underlying performance of our business. This makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
- The terms of our loan and security agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
- We may need additional funding to finance our planned operations, and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate one or more of our product development programs and future commercialization efforts.
- The commercial success of our products will depend upon the degree of market acceptance of our products among hospitals, surgeons and patients.
- We have limited experience in training and marketing and selling our products and we may provide inadequate training, fail to increase our sales and marketing capabilities or fail to develop and maintain broad brand awareness in a cost-effective manner.
- We rely on third-party distributors to effectively distribute our products in certain markets.
- We may not be able to maintain adequate levels of third-party coverage and reimbursement, and third parties may rescind or modify their coverage or delay payments related to our products.
- We face competition from many sources, including larger companies, and we may be unable to compete successfully.
- If we are unable to continue to innovate and improve our products, we could lose customers or market share.
The other 63 risks
- We have limited experience manufacturing our products in large-scale commercial quantities, and we face a number of manufacturing risks that may adversely affect our manufacturing abilities which could delay, prevent or impair our growth.
- We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply shortages and price fluctuations that could negatively affect our business, financial condition and results of operations.
- If we receive a significant number of warranty claims or our products require significant amounts of service after sale, our operating expenses may substantially increase, and our business and financial results will be adversely affected.
- We need to ensure strong product performance and reliability to maintain and grow our business.
- We may not be able to achieve or maintain satisfactory pricing and margins for our products.
- We may encounter difficulties in managing our growth, which could disrupt our operations.
- Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our products and manage our inventory.
- Our information technology systems, or those used by third party service providers, partners, our contractors or consultants, may fail or suffer security breaches, and such failure could negatively affect our business, financial condition and results of operations.
- The use of artificial intelligence in our business, including in our products and internally by our employees or business partners, may expose us to additional legal, regulatory and other risks that could adversely affect our business.
- Actual or perceived failure to comply with data protection, privacy and security laws, regulations, standards and other requirements could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.
- Natural or man-made disasters and other similar catastrophic events outside of our control may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.
- The sizes of the addressable markets for our products have not been established with precision and our potential market opportunity may be smaller than we estimate and may decline.
- Until we are able to achieve broader market acceptance of our products, we may face risks associated with a more concentrated customer base.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our products.
- Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability.
- We may seek strategic alliances, joint ventures or collaborations, or enter into licensing or partnership arrangements in the future and may not be successful in doing so, and even if we are, we may not realize the benefits or costs of such relationships.
- Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
- Changes in United States trade policy, including the imposition of tariffs and the resulting consequences, may have a material adverse impact on our business and results of operations.
- We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.
- We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws, as well as violations of export or import controls or economic sanctions laws and regulations. Any investigation, and the outcome of any investigation, by government agencies of possible violations by us of such laws and regulations could have a material adverse effect on our business.
- Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.
- We may acquire other businesses which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations.
- Risks Related to Governmental Regulation
- Changes to the reimbursement rates for our products and procedures utilizing our products, as well as measures to reduce healthcare costs may adversely impact our business.
- Healthcare reform measures could hinder or prevent the commercial success of our products.
- We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations.
- Our robotic systems and our operations are subject to extensive government regulation and oversight in the United States. If we fail to maintain necessary marketing authorizations for our robotic systems, or if approvals or clearances for future products or modifications to existing products are delayed or not issued, it will negatively affect our business, financial condition and results of operations.
- Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce new products that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products on a timely basis, if at all, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
- Modifications to our marketed products may require new 510(k) clearances, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained.
- Even though we have obtained marketing authorization for our products, we are subject to ongoing regulatory review and scrutiny. Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.
- Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.
- Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.
- Our products may in the future be subject to product recalls that could harm our reputation, business and financial results.
- We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our products.
- Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute our products after clearance or approval is obtained.
- Clinical trials may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects.
- If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products.
- Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- We must comply with environmental and occupational safety laws.
- Risks Related to Our Intellectual Property
- We have to obtain, maintain and protect our intellectual property and failure to do so may adversely impact our competitive position.
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful, and if unsuccessful, the commercial value of our products and services will be adversely affected and our competitive position may be harmed.
- We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture and/or commercialize our current and/or future products or services.
- We may be subject to claims challenging the ownership or inventorship of our patents and other intellectual property and, if unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, or to cease the development, manufacture and commercialization of our current and future products.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.
- We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.
- Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products or services, and could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our current or future patents.
- If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.
- We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, unsuccessful, and could interfere with our ability to sell and market our products or services.
- Our use of “open source” software could subject our proprietary software to general release, adversely affect our ability to sell our current or future products and services, and subject us to possible litigation.
- Intellectual property rights do not necessarily address all potential threats.
- Patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies globally.
- We may not be able to protect our intellectual property and proprietary rights throughout the world.
- We heavily depend on intellectual property licensed from third parties and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.
- Risks Related to Ownership of Our Common Stock
- The market price of our common stock may be volatile or may decline steeply or suddenly regardless of our operating performance, which could result in substantial losses for holders of our common stock, and we may not be able to meet investor or analyst expectations.
- We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
- Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock.
- Delaware law and provisions in our amended and restated certificate of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
- Risks Related to Being a Public Company
- If we are not able to maintain adequate internal control over financial reporting, or if we are unable to produce timely or accurate financial statements, investors may lose confidence in our operating results and the trading price of our common stock could decline.
- If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information.
- The requirements of being a public company may strain our resources, result in more litigation, and divert management’s attention.
- General Risks
- Litigation and other legal proceedings may adversely affect our business.
- General economic and financial market conditions may exacerbate our business risks.
Legal proceedings
From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARReza Zadno, Chief executive officer
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARLarry L. Wood, Board member
- 20SEC EDGARThomas M. Prescott, Board member
- 21SEC EDGARMary Garrett, Board member
- 22SEC EDGARAmy M. Dodrill, Board member
- 23SEC EDGARAntal Rohit Desai, Board member
- 24SEC EDGARFrederic H. Moll, Board member
- 25SEC EDGARMorgan Colby Wood, Board member
- 26SEC EDGARTaylor C. Harris, Board member
- 27SEC EDGARThomas M. Krummel, Board member
- 28SEC EDGARElisabeth Sandoval, Board member
- 29SEC EDGARAlaleh Nouri, General counsel
- 30SEC EDGARExecutive or director change
- 31SEC EDGAREntered a material agreement
- 32SEC EDGARResults of operations
- 33SEC EDGARShareholder vote
- 34SEC EDGARResults of operations
- 35SEC EDGARExecutive or director change
- 36SEC EDGARRegulation FD disclosure
- 37SEC EDGARResults of operations
- 38SEC EDGARResults of operations
- 39SEC EDGARExecutive or director change
- 40SEC EDGARResults of operations
- 41
- 42NasdaqNasdaq calendar
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54